Identification of signature genes for detecting hedgehog signaling activation in gastric cancer

LING YANG[1], SHUHONG HUANG[1], YUEHONG BIAN[1], XIAOLI MA[1], HONGWEI ZHANG[1] and JINGWU XIE[2]

[1]Institute of Developmental Biology, School of Life Sciences, Shandong University, Jinan, Shandong 250100, P.R. China; [2]Wells Center for Pediatric Research, Department of Pediatrics, Division of Hematology and Oncology, Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Received December 21, 2009; Accepted March 3, 2010

DOI: 10.3892/mmr_00000283

Abstract. The aim of this study was to investigate the expression of hedgehog signaling molecules in gastric cancer. *In situ* hybridization, immunohistochemistry and RT-PCR for hedgehog signaling molecules, smoothened (SMO), suppressor of fused [Su(Fu)], and the target genes hedgehog-interacting protein (HIP) and platelet-derived growth factor receptor α (PDGFRα) were performed in 30 gastric cancer and two gastritis specimens. Using *in situ* hybridization, SMO expression was detected in 18/30 cancerous specimens (60%) as well as in 1/2 gastritis specimens (50%). Su(Fu) was expressed in 15/30 (50%), HIP in 14/30 (~47%), and PDGFRα in 6/30 (20%) gastric cancer specimens. Despite the heterogeneous expression pattern, *SMO*, *Su(Fu)* and *PDGFRα* transcripts were highly correlated with the *HIP* transcript in the 30 gastric cancer specimens (p=0.0006, 0.0003 and 0.0441, respectively). Results from the *in situ* hybridization were further confirmed by RT-PCR for the expression of all of the genes and by immunohistochemistry for SMO expression. The findings revealed a set of genes for detecting Hh signaling activation in gastric cancer.

Introduction

The hedgehog (Hh) signaling pathway regulates many processes in tissue development and homeostasis, and the activation of the Hh signaling pathway is associated with many types of human cancer. In the absence of the ligand Hh, hedgehog receptor patched (PTCH) inhibits smoothed (SMO) signaling. When Hh binds to PTCH1, SMO is able to signal, eventually resulting in the formation of activated transcriptional factor Gli molecules and the elevated expression of target genes (e.g., PTCH1, GLI1, HIP and PDGFRα).

Correspondence to: Professor Hongwei Zhang, Institute of Developmental Biology, School of Life Sciences, Shandong University, Jinan, Shandong 250100, P.R. China
E-mail: zhw@sdu.edu.cn; jinxie@iupui.edu.cn

Key words: hedgehog, smoothened, suppressor of fused, hedgehog-interacting protein, PDGFRα, gastric cancer

Recent studies have shown that the Hh pathway is involved in gastrointestinal development (1-9). Molecules such as the transcriptional factors GATA-4, GATA-6 (9), FoxF1 and FoxL1 (5), as well as the ERK (7) and epithelial-mesenchymal transition pathways (6), are reported to be associated with Hh signaling in this process. Increasing evidence shows that Hh signaling plays a role in gastric cancer. Expression of sonic Hh is increased in gastric cancer, and gastric lesions are associated with the methylation status of the sonic hedgehog (Shh) promoter (10). Nuclear translocation of Gli1 was found to be higher in undifferentiated-type tumors and to be positively correlated with lymph node metastasis in gastric carcinoma (11). Hh signaling was found to promote gastric cancer cell proliferation (12,13), epithelial-mesenchymal transition (6), mobility and invasiveness (14). We previously demonstrated that overexpression of Hh and its target genes, Gli1 and PTCH1, occurs in gastric tumor tissue. We also showed that the Smo antagonist or Shh neutralizing antibodies inhibit growth and induce apoptosis in gastric cancer cells (15).

It is not known which molecules in the Hh signaling pathway can be used to detect Hh signaling activation in gastric cancer. Elucidation of the Hh signaling activation signature will aid in the clinical diagnosis of gastric cancer and will allow us to understand Hh signaling in gastric cancer in greater detail. In the present study, we analyzed the expression of the *SMO*, *HIP*, *Su(Fu)* and *PDGFRα* genes in 30 gastric cancer and two gastritis specimens using *in situ* hybridization, RT-PCR and immunohistochemistry.

Materials and methods

Tumor specimens. Thirty cases of gastric cancer and two cases of gastritis were received as discarded materials from the Shangdong QiLu Hospital, Jinan, China. Pathology reports and H&E staining of each specimen were reviewed to determine the nature of the disease and the tumor histology. The gastric cancer specimens were categorized into three subtypes according to the WHO guidelines (16) as follows: tubular adenocarcinoma (26 cases), papillary adenocarcinoma (2 cases) and squamous cell carcinoma (2 cases) (Table I).

In situ hybridization. Tissue sections (6-μm) were mounted onto poly-L-lysine slides. Following deparaffinization, the

Table I. Gastric cancer specimens and summary of *Shh*, *Ptch*, *Gli1*, *Smo*, *Hip*, *Su(Fu)* and *PDGFRα* expression from *in situ* hybridization.

No.	Age	Gender	Pathological diagnosis	Stage	SHH[a]	PTCH[a]	GLI1[a]	SMO	SU(FU)	HIP	PDGFRα
1	50	M	Gastritis		-	-	-	±	-	-	-
2	62	M	Gastritis		-	-	-	-	-	-	-
3	69	M	Tubular adenocarcinoma (W)	III	-	-	-	±	-	-	-
4	72	M	Tubular adenocarcinoma (W)	III	+	+	+	+	+	+	±
5	29	F	Tubular adenocarcinoma (W)	III	±	-	-	-	-	±	-
6	54	F	Tubular adenocarcinoma (M)	II	+	+	+	±	+	±	-
7	68	M	Tubular adenocarcinoma (M)	II	+	±	+	±	+	±	-
8	59	F	Tubular adenocarcinoma (M)	III	±	-	-	±	-	-	-
9	73	M	Tubular adenocarcinoma (M)	III	-	-	-	-	-	-	-
10	51	M	Tubular adenocarcinoma (M)	III	±	±	±	+	+	-	-
11	54	M	Tubular adenocarcinoma (P)	III	+	-	-	-	-	-	-
12	49	M	Tubular adenocarcinoma (P)	III	+	+	+	+	+	+	+
13	68	M	Tubular adenocarcinoma (P)	II	-	-	-	±	+	+	-
14	67	M	Tubular adenocarcinoma (P)	I	-	-	-	-	-	-	-
15	59	M	Tubular adenocarcinoma (P)	III	+	±	±	±	+	+	-
16	60	M	Tubular adenocarcinoma (P)	III	+	-	-	-	-	-	-
17	69	M	Tubular adenocarcinoma (P)	III	+	+	+	+	+	+	-
18	70	F	Tubular adenocarcinoma (P)	II	+	+	+	+	+	-	+
19	59	M	Tubular adenocarcinoma (P)	III	+	±	±	±	±	-	-
20	69	M	Tubular adenocarcinoma (P)	III	-	-	-	-	-	-	-
21	56	M	Tubular adenocarcinoma (P)	III	-	-	-	-	-	-	-
22	65	M	Tubular adenocarcinoma (P)	III	-	-	-	-	-	-	-
23	50	F	Tubular adenocarcinoma (P)	II	-	-	-	-	-	-	-
24	77	M	Tubular adenocarcinoma (P)	II	-	-	-	-	-	-	-
25	71	M	Tubular adenocarcinoma (P)	III	-	-	-	-	-	-	-
26	68	M	Tubular adenocarcinoma (P)	III	+	+	+	+	+	±	-
27	57	F	Tubular adenocarcinoma (P)	II	-	-	-	-	-	-	-
28	49	M	Tubular adenocarcinoma (P)	III	±	±	±	+	-	±	-
29	50	M	Papillary adenocarcinoma	I	+	+	+	+	+	+	+
30	67	M	Papillary adenocarcinoma	III	+	±	+	+	+	±	+
31	65	M	Squamous cell carcinoma (W)	II	+	+	+	±	+	+	-
32	65	M	Squamous cell carcinoma (P)	III	+	+	+	+	+	+	+

[a]Results of the *Shh*, *Ptch* and *Gli1 in situ* hybridization are from our previous study (15).

sections were rehydrated in a series of dilutions of ethanol. To enhance the signal and facilitate probe penetration, sections were immersed in 0.3% Triton X-100 solution for 15 min at room temperature, followed by treatment with proteinase K (20 μg/ml) for 20 min at 37˚C. The sections were then incubated with 4% (v/v) paraformaldehyde/PBS for 5 min at 4˚C. After washing with PBS and 0.1 M triethanolamine, the slides were incubated with pre-hybridization solution (50% formamide, 50% 4X standard saline citrate) for 2 h at 37˚C. The probe was added to each tissue section at a concentration of 1 μg/ml and hybridized overnight at 42˚C. After high-stringency washing (2X SSC twice, 1X SSC twice, 0.5X SSC twice at 37˚C), sections were incubated with an alkaline phosphatase-conjugated sheep antidigoxigenin antibody, which catalyzed a color reaction with the NBT/BCIP (nitro-blue-tetrazolium/5-bromo-4-chloro-3-indolyl phosphate) substrate (Roche). Blue staining indicated strong hybridization. Sense probes were used as negative controls in all hybridizations, and no positive signals were observed.

Immunohistochemistry. The smoothened antibody (ab13118-50; Abcam, Cambridge, UK) was used to perform immunohistochemistry on the tissue sections (6-μm). The procedure of immunohistochemistry was as described elsewhere (15). Negative controls were performed by omitting the first antibody.

RT-PCR. Total RNAs were extracted using an RNA extraction kit according to the manufacturer's instructions (Promega, Madison, WI, USA). PCR was performed using



Figure 1. (A) Expression of *HIP* and *PDGFRα* in gastric cancer. The *HIP* and *PDGFRα* transcripts (indicated by arrows) were detected by *in situ* hybridization in poorly differentiated SSC (a and e) and papillary adenocarcinoma (c and g); b, d, f and h were the controls using the respective sense probe (x200). (B) RT-PCR detection of *SMO*, *HIP*, *Su(Fu)* and *PDGFRα* transcripts in gastric cancer. β-actin was used as the endogenous reference. Numbers listed indicate specimen number. (C) Expression of *SMO* and *Su(Fu)* in gastric cancer. The *SMO* and *Su(Fu)* transcripts (indicated by arrows) were detected by *in situ* hybridization. Positive staining was noted in poorly differentiated SSC (a and e) and moderately differentiated tubular adenocarcinoma (c and g); b, d, f and h were the controls using the respective sense probe (x200). (D) Expression of SMO protein in gastric cancer. SMO protein (indicated by arrows) was detected by immunohistochemistry in moderately differentiated tubular adenocarcinoma (a); b is the negative control without the primary antibody (x200).

10 pmol of each primer in a standard 50-ml PCR reaction containing 100 mM dNTPs and cDNA from human tissue cDNA expression libraries as a template. The primer sequences are listed in Table II. DNA was amplified by Taq DNA polymerase for 30 cycles and subsequently run on a 0.8% agarose gel. The bands were visualized under UV light prior to image capture.

Statistical analysis. The two-tailed χ^2 test was used for all statistical analysis.

Results

Expression of Hh target genes in gastric cancer. An increasing number of putative Hh target genes have been identified, but only a few have been evaluated for expression in gastric cancer (15). HIP is a known Hh target gene that encodes a negative regulator of the pathway, forming a negative feedback loop. Several studies have reported that elevated HIP expression indicates activated Hh signaling in human cancer (17,18). PDGFRα expression is elevated in basal cell carci-

Table II. Primers used in RT-PCR.

Gene name	Primers
SMO	F: AAGGCCACGCTGCTCATCTGG R: CATTGAGGTCAAAGGCCAAGC
Su(Fu)	F: AGAGTGCCGCCGCCTTTACC R: ACGGGCTGCATCTGTGGGTC
HIP	F: TTCCATACCAAGGAGCAACC R: TCTTGCCACTGCTTTGTCAC
PGDFRα	F: GCTTTCATTACCCTCTATCCT R: GAATCATCCTCCACGA

nomas, which exhibits activation of the Hh pathway (19). To assess the expression of HIP and PDGFRα in gastric cancer, we first performed *in situ* hybridization analysis. Expression of the HIP transcript was detected in 14/30 gastric cancer specimens (~47%). The majority of the expression was detected in tumor tissue, rather than in the stroma (Table I). While the antisense probe provided a good signal (Fig. 1A, a and c, arrows), the sense probe did not yield any signals (Fig. 1A, b and d), indicating the specificity of *in situ* hybridization. Further analysis indicated that HIP expression was highly correlated with the expression of PTCH1 and Gli1, as determined in a previous study (15) (p=0.0003), indicating that the detection of HIP is as effective as the detection of Gli1 or PTCH1 in gastric cancer.

Expression of PDGFRα was detected in 6/30 gastric cancer specimens (20%). Most samples also expressed Gli1, PTCH1 and HIP (p=0.0062, 0.0062 and 0.0441, respectively). This indicates that, unlike HIP, PDGFRα expression is only detected in a subset of gastric cancer specimens with activated Hh signaling activation (Table I, Fig. 1A, e-h).

To confirm the results from the *in situ* hybridization, we performed RT-PCR in selected specimens in which the tumor content was >70% of the tissue mass. As shown in Fig. 1B, HIP and PDGFRα transcripts were detected in specimens 12 and 4, but not in specimens 14 and 3, which is consistent with the *in situ* hybridization data (Table I). Similarly, specimen 26 had a detectable HIP transcript but not a PDGFRα transcript (Fig. 1B and Table I).

Taken together, we found that the transcripts of HIP, Gli1 and PTCH1 were highly expressed in the gastric cancer specimens, whereas the PDGFRα transcript was detectable only in a subset of cancer exhibiting Gli1, PTCH1 and HIP expression.

Expression of SMO and Su(Fu) in gastric cancer. In addition to Hh target genes, we also investigated the expression of Hh signaling molecules in gastric cancer. SMO is a key signal transducer of the Hh pathway, and deletion of SMO results in the blockage of Hh signaling in mouse embryos (20). A previous study revealed elevated expression of SMO in prostate cancer (21). Su(Fu) is a negative regulator of the Hh pathway, inhibiting the function of Gli molecules through several mechanisms (22). Studies have indicated that reduced expression of Su(Fu) is one mechanism by which Hh signaling is activated (23).

First, SMO expression was examined by *in situ* hybridization. Eighteen gastric cancer specimens and one gastritis tissue specimen had a detectable level of SMO transcript (Table I and Fig. 1C, e and g, arrows). Most of the signal was in the tumor tissue, not in the stroma. Since no signals were detected with the sense probe of SMO, our *in situ* hybridization method was very reliable. RT-PCR was performed using selected specimens to confirm the data from the *in situ* hybridization. SMO expression detected by *in situ* hybridization was confirmed by RT-PCR (Fig. 1B). In one sample (specimen 24), the SMO transcript was detected only by RT-PCR. This was not unexpected, since PCR amplification is more sensitive in detecting gene expression. We also examined SMO protein expression in gastric cancer tissues using SMO-specific antibodies. As shown in Fig. 1D, SMO expression was found in the tissues with a detectable SMO transcript by *in situ* hybridization and RT-PCR. In comparison with HIP and other Hh target genes, the SMO transcript was detected in both the cancerous and gastritis tissues. Furthermore, the SMO transcript was detected in tissues with detectable expression of the Hh target genes HIP, Gli1 and PTCH1 (Table I). These results indicate that SMO expression does not represent Hh target gene activation in gastric cancer.

Next, the expression of Su(Fu) was examined by *in situ* hybridization and RT-PCR. No expression of Su(Fu) was detected in the gastritis samples. The sense probe of Su(Fu) did not detect any signals, while the antisense probe revealed the Su(Fu) transcript in 15 gastric cancer specimens (Fig. 1C, a-d and Table I). In tumors with detectable Hh target genes (indicating activation of Hh signaling), reduced expression of Su(Fu) was not found, suggesting the loss of Su(Fu) is not a common mechanism of Hh signaling activation. The results of RT-PCR confirmed the findings of the *in situ* hybridization.

Taken together, the data indicated that elevated expression of SMO or loss of Su(Fu) expression are not common in gastric cancer.

Discussion

Detection of Hh target gene expression is an important step in the identification of Hh signaling activation in human cancer. However, previous studies have examined only a few Hh target genes. To better understand Hh signaling activation in gastric cancer and to develop methods for its early diagnosis, we investigated the expression of several Hh target genes in gastric cancer. The results of HIP expression are consistent with our previous findings regarding Gli1 and PTCH1 (Table I). By contrast, only a subset of tumors with activated Hh signaling expressed PDGFRα. A high correlation was found between the HIP transcript and the PTCH1 or Gli1 transcript in gastric cancer (p=0.0001). These findings suggest that the expression of HIP, Gli1 and PTCH1 may be used to detect Hh signaling activation in gastric cancer. Although PDGFRα expression can be used to detect tumors with activated Hh signaling, many tumors go undetected due to its insensitivity. It has been reported that transcriptional silencing of the HIP protein is present in gastrointestinal cancer cell lines and a subset of gastric cancer tissues (24). Our studies did not reveal any reduced expression of HIP in tumors with detectable expression of Gli1 and PTCH1, suggesting that

post-transcriptional regulation of *HIP* in gastric cancer is not a major mechanism for Hh signaling activation.

Several reports have indicated that alterations in Hh signaling molecules may be responsible for Hh signaling activation. Su(Fu) is an essential repressor in mammalian Hh signaling (25). Mutations in Su(Fu) have been found in cancer cell lines and tumors (18,26,27), and the SCL/TAL1 interrupting locus depresses GLI1 from negative control of Su(Fu) in pancreatic cancer cells (28). However, we did not observe a significant alteration in the expression of Su(Fu) in the gastric cancer samples, suggesting that Su(Fu) inactivation is not very common in gastric cancer.

SMO expression was found to be elevated in a subset of prostate cancer specimens (21). Our data did not show any increase in SMO expression in gastric cancer. Whether the SMO transcript level can be used to detect Hh signaling activation in other types of tumors remains to be determined.

Expression of PDGFRα has been detected in several types of tumors (29-32), and has been found to be involved in tumor cell growth and metastasis (33-36). It has been reported that Gli1 activates PDGFRα in C3H10T1/2 cells (19); we also found that transcripts of *PDGFRα* were highly co-expressed with Hh signaling. Although the expression of PDGFRα is not as common as that of Gli1 in gastric cancer, identification of the mechanism by which PDGFRα is regulated may further contribute to the understanding of Hh-mediated carcinogenesis. It is known that PDGFRα increases tumor cell proliferation and metastasis. Currently, clinical therapeutics against PDGFRα function are achieved through the administration of STI571 (37). We envision that gastric cancer with detectable expression of PDGFRα may be eligible for treatment with STI571.

In the present study, target gene HIP expression was detected in approximately 47% of the gastric cancer specimens. HIP expression was highly correlated with the expression of PTCH1 and Gli1, indicating that the detection of HIP is as effective as the detection of Gli1 or PTCH1 in gastric cancer. SMO expression was detected in both the cancerous (60%) and gastritis (50%) specimens. Elevated expression of SMO is not common in gastric cancer. Su(Fu) was expressed in 50% of the gastric cancer specimens. Reduced expression of Su(Fu) was not found in the tumors with activated Hh signaling. Despite the heterogeneous expression pattern, the *SMO*, *Su(Fu)* and *PDGFRα* transcripts were highly correlated with the *HIP* transcript in the 30 gastric cancer specimens (p=0.0006, 0.0003 and 0.0441, respectively). The results reveal a set of genes for detecting Hh signaling activation in gastric cancer.

Acknowledgements

This study was supported by grants from the NCI (no. R01CA94160), the NIEHS (no. ES06676), the National Natural Science Foundation of China (nos. 30671072 and 30570967), and the Ministry of Science and Technology of China (nos. 2007CB947100 and 2007CB815800). Author contributions were as follows: Hongwei Zhang and Jingwu Xie designed the research protocol; Ling Yang, Shuhong Huang, Yuehong Bian and Xiaoli Ma performed the research; Ling Yang and Jingwu Xie analyzed the data and prepared the manuscript.

References

1. Van den Brink GR, Hardwick JC, Tytgat GN, *et al*: Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology 121: 317-328, 2001.
2. Kim JH, Huang Z and Mo R: Gli3 null mice display glandular overgrowth of the developing stomach. Dev Dyn 234: 984-991, 2005.
3. Van den Brink GR, Hardwick JC, Nielsen C, *et al*: Sonic hedgehog expression correlates with fundic gland differentiation in the adult gastrointestinal tract. Gut 51: 628-633, 2002.
4. Kang DH, Han ME, Song MH, *et al*: The role of hedgehog signaling during gastric regeneration. J Gastroenterol 44: 372-379, 2009.
5. Madison BB, McKenna LB, Dolson D, Epstein DJ and Kaestner KH: FoxF1 and FoxL1 link hedgehog signaling and the control of epithelial proliferation in the developing stomach and intestine. J Biol Chem 284: 5936-5944, 2009.
6. Ohta H, Aoyagi K, Fukaya M, *et al*: Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers. Br J Cancer 100: 389-398, 2009.
7. Osawa H, Ohnishi H, Takano K, *et al*: Sonic hedgehog stimulates the proliferation of rat gastric mucosal cells through ERK activation by elevating intracellular calcium concentration. Biochem Biophys Res Commun 344: 680-687, 2006.
8. Ramalho-Santos M, Melton DA and McMahon AP: Hedgehog signals regulate multiple aspects of gastrointestinal development. Development 127: 2763-2772, 2000.
9. Haveri H, Westerholm-Ormio M, Lindfors K, *et al*: Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol 8: 9, 2008.
10. Wang LH, Choi YL, Hua XY, *et al*: Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions. Mod Pathol 19: 675-683, 2006.
11. Yanai K, Nagai S, Wada J, *et al*: Hedgehog signaling pathway is a possible therapeutic target for gastric cancer. J Surg Oncol 95: 55-62, 2007.
12. Ohta M, Tateishi K, Kanai F, *et al*: p53-independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res 65: 10822-10829, 2005.
13. Yanai K, Nakamura M, Akiyoshi T, *et al*: Crosstalk of hedgehog and Wnt pathways in gastric cancer. Cancer Lett 263: 145-156, 2008.
14. Yoo YA, Kang MH, Kim JS and Oh SC: Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis 29: 480-490, 2008.
15. Ma X, Chen K, Huang S, *et al*: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 26: 1698-1705, 2005.
16. Sarbia M, Becker KF and Hofler H: Pathology of upper gastrointestinal malignancies. Semin Oncol 31: 465-475, 2004.
17. Bonifas JM, Pennypacker S, Chuang PT, *et al*: Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol 116: 739-742, 2001.
18. Sheng T, Li C, Zhang X, *et al*: Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 3: 29, 2004.
19. Xie J, Aszterbaum M, Zhang X, *et al*: A role of PDGFRalpha in basal cell carcinoma proliferation. Proc Natl Acad Sci USA 98: 9255-9259, 2001.
20. Wijgerde M, McMahon JA, Rule M and McMahon AP: A direct requirement for Hedgehog signaling for normal specification of all ventral progenitor domains in the presumptive mammalian spinal cord. Genes Dev 16: 2849-2864, 2002.
21. Karhadkar SS, Bova GS, Abdallah N, *et al*: Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431: 707-712, 2004.
22. Barnfield PC, Zhang X, Thanabalasingham V, Yoshida M and Hui CC: Negative regulation of Gli1 and Gli2 activator function by Suppressor of fused through multiple mechanisms. Differentiation 73: 397-405, 2005.
23. Chi S, Huang S, Li C, *et al*: Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett 244: 53-60, 2006.
24. Taniguchi H, Yamamoto H, Akutsu N, *et al*: Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer. J Pathol 213: 131-139, 2007.

25. Svard J, Heby-Henricson K, Persson-Lek M, *et al*: Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev Cell 10: 187-197, 2006.
26. Reifenberger J, Wolter M, Knobbe CB, *et al*: Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152: 43-51, 2005.
27. Taylor MD, Liu L, Raffel C, *et al*: Mutations in SUFU predispose to medulloblastoma. Nat Genet 31: 306-310, 2002.
28. Kasai K, Inaguma S, Yoneyama A, Yoshikawa K and Ikeda H: SCL/TAL1 interrupting locus derepresses GLI1 from the negative control of suppressor-of-fused in pancreatic cancer cells. Cancer Res 68: 7723-7729, 2008.
29. Rikova K, Guo A, Zeng Q, *et al*: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203, 2007.
30. Taja-Chayeb L, Chavez-Blanco A, Martinez-Tlahuel J, *et al*: Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int 6: 22, 2006.
31. Zhang T, Sun HC, Xu Y, *et al*: Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 11: 8557-8563, 2005.
32. Matei D, Emerson RE, Lai YC, *et al*: Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25: 2060-2069, 2006.
33. Jechlinger M, Sommer A, Moriggl R, *et al*: Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116: 1561-1570, 2006.
34. Lev DC, Kim SJ, Onn A, *et al*: Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 11: 306-314, 2005.
35. Russell MR, Jamieson WL, Dolloff NG and Fatatis A: The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 28: 412-421, 2009.
36. Wehler TC, Frerichs K, Graf C, *et al*: PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol Rep 19: 697-704, 2008.
37. Heinrich MC, Corless CL, Demetri GD, *et al*: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349, 2003.